CT/NG Testing Services - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the CT/NG testing services market size is projected to expand from USD 2.54 billion in 2025 and USD 2.73 billion in 2026 to USD 3.93 billion by 2031, registering a CAGR of 7.53% between 2026 to 2031.

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Asymptomatic Infection Burden
  • 4.2.2 Broader Screening for Sexually Active Under-25 Populations
  • 4.2.3 Multiplex CT/NG Panels Reducing Repeat Sample Collection
  • 4.2.4 Home Collection and Telehealth-Fulfilled Testing Adoption
  • 4.2.5 Extragenital Testing Expansion in High-Risk Screening Protocols
  • 4.2.6 Reimbursement Support for Preventive STI Screening
• 4.3 Market Restraints
  • 4.3.1 Social Stigma and Privacy Concerns
  • 4.3.2 Cost Pressure on Multiplex Molecular Assays
  • 4.3.3 Reimbursement Gaps for Asymptomatic and Panel Testing
  • 4.3.4 Regulatory Complexity for Home-Use and Point-of-Care Assays
• 4.4 Value and Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size and Growth Forecasts

• 5.1 By Test Type
  • 5.1.1 Chlamydia (CT) Testing Services
  • 5.1.2 Gonorrhea (NG) Testing Services
  • 5.1.3 Combined CT/NG Testing Services
• 5.2 By Technology
  • 5.2.1 Nucleic Acid Amplification Testing (NAAT) Services
  • 5.2.2 Culture-Based Testing Services
  • 5.2.3 Immunoassay-Based Testing Services
  • 5.2.4 Others
• 5.3 By Sample Type
  • 5.3.1 Urine Samples
  • 5.3.2 Vaginal and Cervical Swabs
  • 5.3.3 Urethral Swabs
  • 5.3.4 Rectal and Pharyngeal Swabs
  • 5.3.5 Others
• 5.4 By Testing Mode
  • 5.4.1 Centralized Laboratory Testing
  • 5.4.2 Point-of-Care Testing Services
  • 5.4.3 At-Home Collection and Laboratory Testing Services
• 5.5 By End User
  • 5.5.1 Reference Laboratories
  • 5.5.2 Hospital and Clinical Laboratories
  • 5.5.3 Public Health Laboratories
  • 5.5.4 Others
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Aclara Technologies (ACL Laboratories)
  • 6.3.2 ARUP Laboratories
  • 6.3.3 binx health
  • 6.3.4 BioReference Laboratories
  • 6.3.5 Cerba Healthcare
  • 6.3.6 Clinical Reference Laboratory
  • 6.3.7 Eurofins Scientific SE
  • 6.3.8 Healius Limited
  • 6.3.9 Labcorp
  • 6.3.10 LetsGetChecked
  • 6.3.11 Mayo Clinic Laboratories
  • 6.3.12 PathCare.AI
  • 6.3.13 Quest Diagnostics Incorporated
  • 6.3.14 Sonic Healthcare Limited
  • 6.3.15 SYNLAB AG
  • 6.3.16 Unilabs

7 Market Opportunities and Future Outlook

• 7.1 White-space and Unmet-Need Assessment